Media coverage about Intersect ENT (NASDAQ:XENT) has been trending negative recently, AlphaOne Sentiment Analysis reports. AlphaOne, a service of Accern, ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Intersect ENT earned a media sentiment score of -0.35 on AlphaOne’s scale. AlphaOne also gave media headlines about the medical equipment provider an impact score of 0 out of 100, meaning that recent news coverage is extremely unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have effected AlphaOne Sentiment Analysis’s scoring:
- Insider Selling: Intersect ENT, Inc. (XENT) Insider Sells 20,000 Shares of Stock (americanbankingnews.com)
- Intersect ENT, Inc. (XENT) stock price is showing discouraging … – Stocks Gallery (stocksgallery.com)
- ETFs with exposure to Intersect ENT, Inc. : June 16, 2017 (finance.yahoo.com)
- Intersect ENT, Inc. :XENT-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 (finance.yahoo.com)
- Financial Survey: Intersect ENT (XENT) vs. VWR Corporation (VWR) (americanbankingnews.com)
Several research firms have recently commented on XENT. Wedbush upped their target price on Intersect ENT from $25.00 to $26.00 and gave the company an “outperform” rating in a research report on Wednesday, May 3rd. Canaccord Genuity reaffirmed a “buy” rating on shares of Intersect ENT in a research report on Wednesday, May 3rd. Northland Securities upped their target price on Intersect ENT from $17.00 to $22.00 and gave the company an “outperform” rating in a research report on Thursday, May 4th. Zacks Investment Research upgraded Intersect ENT from a “strong sell” rating to a “hold” rating in a research note on Wednesday, May 3rd. Finally, William Blair reiterated an “outperform” rating on shares of Intersect ENT in a research note on Wednesday, May 10th. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $18.60.
Intersect ENT (NASDAQ:XENT) traded up 1.34% during mid-day trading on Monday, reaching $26.40. The company had a trading volume of 242,626 shares. The firm’s market capitalization is $759.58 million. The firm has a 50-day moving average price of $24.29 and a 200 day moving average price of $16.50. Intersect ENT has a 12-month low of $7.65 and a 12-month high of $27.98.
Intersect ENT (NASDAQ:XENT) last posted its earnings results on Tuesday, May 2nd. The medical equipment provider reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. The business had revenue of $20.47 million for the quarter, compared to the consensus estimate of $19.39 million. Intersect ENT had a negative net margin of 28.71% and a negative return on equity of 20.49%. Analysts expect that Intersect ENT will post ($0.74) EPS for the current year.
In other Intersect ENT news, insider Lisa D. Earnhardt sold 20,000 shares of the firm’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $26.10, for a total transaction of $522,000.00. Following the transaction, the insider now owns 583,493 shares of the company’s stock, valued at approximately $15,229,167.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 81,250 shares of company stock worth $1,781,763 in the last three months. Insiders own 13.90% of the company’s stock.
Intersect ENT Company Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with our FREE daily email newsletter.